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Background: Patient decision aids (PDAs) should provide evidence- based informa-
tion so patients can make informed decisions. Yet, PDA developers do not have an 
agreed- upon process to select, synthesize and present evidence in PDAs.
Objective: To reach the consensus on an evidence summarization process for PDAs.
Design: A two- round modified Delphi survey.
Setting and participants: A group of international experts in PDA development in-
vited developers, scientific networks, patient groups and listservs to complete Delphi 
surveys.
Data collection: We emailed participants the study description and a link to the on-
line survey. Participants were asked to rate each potential criterion (omit, possible, 
desirable, essential) and provide qualitative feedback.
Analysis: Criteria in each round were retained if rated by >80% of participants as 
desirable or essential. If two or more participants suggested rewording, reordering or 
merging, the steering group considered the suggestion.
Results: Following two Delphi survey rounds, the evidence summarization process 
included defining the decision, reporting the processes and policies of the evidence 
summarization process, assembling the editorial team and managing (collect, man-
age, report) their conflicts of interest, conducting a systematic search, selecting and 
appraising the evidence, presenting the harms and benefits in plain language, and 
describing the method of seeking external review and the plan for updating the evi-
dence (search, selection and appraisal of new evidence).
Conclusion: A multidisciplinary stakeholder group reached consensus on an evidence 
summarization process to guide the creation of high- quality PDAs.
Patient contribution: A patient partner was part of the steering group and involved 
in the development of the Delphi survey.
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1  | BACKGROUND
Patient decision aids (PDAs) are tools that help patients and their clini-
cians make preference- sensitive decisions together.1 They are typically 
defined as ‘evidence- based tools designed to help patients make spe-
cific and deliberated choices among healthcare options.1 PDAs supple-
ment (rather than replace) clinicians' counseling about options’.1,2 They 
promote patient engagement in health decision making and collabora-
tion between patients and their care team, increase patient knowledge 
and align patients’ choices with their preferences.1 Further, PDAs are 
being increasingly designed with, and for, patients with lower health 
literacy skills. For example, Option Grid PDAs are written at a sixth- 
grade reading level, and some versions include pictures that have been 
user- tested with low literacy patients to improve their understanding 
and recall of the health information.3- 7 Therefore, the information in-
cluded in PDAs can substantially affect patients' decisions. For this 
reason, patients and clinicians expect the information in PDAs to be 
evidence- based and rigorously selected and summarized.
However, the approach that PDA developers use to select and 
summarize the evidence in PDAs is inconsistent and often incom-
plete or not described.2 A recent international survey of 15 PDA 
developers confirms that they do not have an agreed- upon, stan-
dardized process to select and summarize evidence.8 They did not al-
ways document the evidence selection and summarization process.8 
Most organizations reported using existing systematic reviews and 
clinical practice guidelines to select and summarize information for 
PDAs.8 Less than half reported using a standard, documented ap-
proach to guide the evidence selection and summarization.8 When 
the approach was documented, the documents offered varying 
levels of detail.8 Common evidence summarization steps identified 
were as follows: tool- relevant question formation, search strategies, 
evidence appraisals and updating policies.8 There was no standard-
ized process across organizations to summarize evidence for PDAs.8
The International Patient Decision Aids Standards (IPDAS) 
Collaboration developed criteria for assessing the quality of PDAs.9 
These criteria are also used by PDA producers to guide the devel-
opment of the aids. However, only five items of the IPDAS checklist 
cover the selection and summarization of evidence, and none provide 
guidance about recommended methods for evidence selection and 
summarization for PDAs.9 A 2013 review of the literature conducted 
by the IPDAS working group on the synthesis of scientific evidence 
highlighted the importance of rigorously selecting and summarizing 
evidence used to populate a PDA. They did not provide clear prac-
tical guidance on how to conduct evidence summarization for the 
development of PDAs, except recommending that developers apply 
the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) methodology.10 Furthermore, the IPDAS in-
strument and the IPDAS minimum standards do not offer additional 
information or guidance on the steps required to select and summarize 
evidence- based information for PDAs.11,12 As part of a recent update 
of IPDAS, researchers analysed the evidence characteristics of 471 
publicly available PDAs, and only 14% of them reported ‘at least one of 
the steps used to select the evidence included in the decision aid, such 
as how it was searched for, appraised, or summarized’.13 Other efforts 
to evaluate or certify the quality of PDAs have emerged,14 but none of 
those standards or certification bodies describe recommended meth-
ods and criteria that PDA producers should follow when selecting and 
summarizing evidence for patient- facing tools.
Although consensual and validated methods for evidence sum-
marization exist for other evidence resources, such as clinical practice 
guidelines, there is no agreed- upon process for the selection and sum-
marization of evidence for PDAs. Evidence summarization processes 
for other resources have become increasingly standardized, which 
promotes transparency and rigour, while minimizing the risk of bias in 
the end product.2,15- 23 The same level of scrutiny is justified when de-
veloping PDAs, as they may directly influence patient care and decision 
making. The selection and identification of patient- relevant outcomes, 
analysis of patient concerns and priorities, description of the quality 
of evidence and communication of uncertainty in ways that patients 
understand warrant the development of an agreed- upon process and 
related steps and criteria that are specific to PDAs. The target audi-
ence, scope and content differ substantially enough from clinical prac-
tice guidelines to require a tailored evidence summarization process. 
Additionally, the IPDAS Collaboration imposes some prerequisites on 
the evidence summarization process on which the PDA will be based. 
For example, the IPDAS Collaboration requires that developers sum-
marize the evidence regarding all health options available to a patient 
facing a specific health problem, with positive and negative features 
of each option presented with equal amounts of details.24 Efforts to 
develop an agreed- upon evidence summarization process for PDAs 
should incorporate the substantial body of related evidence summari-
zation guidance previously developed by other groups.17
The aim of the study was to reach consensus, using a modified 
Delphi survey, on a process, related steps and criteria for selecting 
and summarizing evidence for PDAs. This will, in turn, assist PDA 
developers in improving the transparency and rigour, while minimiz-




Our study protocol was published, and a summary is presented 
here.25 The modified Delphi method has been previously used in 
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the development of a quality criteria framework for PDAs.2,26 We 
used this method because it is the most practical and scalable to 
obtain feedback from a large number of stakeholders in different 
geographical locations. We predetermined that there would be two 
Delphi rounds, with a third if needed. The anonymous responses 
from participants in the first round were fed back to them in the sec-
ond round. Throughout the process, a panel of relevant stakehold-
ers in the field of PDA development provided feedback about the 
evolving set of evidence summarization steps and criteria. Ethical 
approval was received from the Committee for the Protection of 
Human Subjects (STUDY00031042).
2.2 | Participants
To maximize the generalizability and applicability of the criteria, 
we invited the following groups to complete the surveys: (1) the 
Global Inventory of Patient Decision Support Developers, which 
includes all known developers of PDAs who created or updated a 
tool within the last five calendar years (the inventory was last up-
dated 4 October 2019), (2) all members of the IPDAS group, (3) the 
shared decision- making listserv, (4) the Society for Participatory 
Medicine listserv, (5) an overdiagnosis Google Group, (6) the 
evidence- based health- care listserv, (7) the Society for Medical 
Decision Making, (8) the Society of Behavioural Medicine (Health 
Decision Making Interest Group), (9) the HTAi- ISG patient involve-
ment listserv, (10) the GRADE working group, (11) the Guidelines 
International Network, (12) a convenience sample of policymak-
ers with interest and expertise in PDA certification, (13) the BMJ 
patient group and (14) the ProPublica Patient Safety Community. 
Membership in one of the groups listed above was the only crite-
rion for inclusion in our study.
2.3 | Steering group
We convened a steering group to oversee the project and make stra-
tegic decisions about the study design, data collection and analysis 
processes, as well as agree on a final set of steps and criteria. The 
steering group also generated an initial set of criteria for the Delphi 
process and managed the distribution of the survey.
An invitation to join the steering group was posted in the Shared@
Shared Decision Making Network Facebook group (745 members) on 
30 June 2017. The post invited all members in the Facebook group 
to join an in- person meeting about evidence summarization during 
the International Shared Decision Making (ISDM) conference held in 
Lyon, France, between 2 and 5 July 2017. Following the conference, 
a summary of the meeting was posted on Facebook for those who 
expressed interest in evidence summarization of PDAs but could not 
attend.
The steering group convened by videoconference in September 
2017. It included 9 international experts in the areas of PDA develop-
ment, evaluation and implementation, evidence summarization and 
clinical practice guidelines. The experts were based in the United 
States (n = 6), Canada (n = 1), Australia (n = 1) and Spain (n = 1), all 
of whom are authors of this study. The steering group also included 
1 patient representative. To avoid contaminating Delphi results or 
duplicating their views, the steering group members unanimously 
decided not to complete the Delphi surveys.
2.4 | Survey development
At the first meeting of the ISDM conference in Lyon, France, the 
steering group developed a spreadsheet that detailed the evidence 
summarization process inherent to PDA development. The first draft 
of the process included 18 criteria. The 18 criteria were combined 
with the 8 existing standards for the summarization of clinical prac-
tice guidelines as outlined by the National Academy of Medicine and 
US Preventive Services Task Force Standards.27 These 26 criteria 
made up the first draft of the proposed evidence summarization 
process and steps. The draft was embedded in a Google Document 
and shared with the members of the steering group so they could it-
eratively refine and finalize the process. Overall, this work produced 
three separate iterations of the evidence summarization process 
with slightly different wording and grouping of steps and criteria. 
Each iteration was reviewed and discussed by the steering group 
members. After no additional changes were suggested, four chrono-
logical phases of evidence summarization, consisting of 48 criteria 
categorized into 13 steps, made up the first survey round in April 
2018 (see Appendix S1).
2.5 | Data collection
2.5.1 | Round 1 survey
The round 1 survey invitation (see Appendix S2) was sent by email 
and provided a brief outline of the study and the link to the online 
survey. Consent was inferred by participants’ completion of the sur-
vey. The first page of the survey was a brief participant information 
sheet. Following the information sheet, participants were asked to 
complete demographic questions and provide their email address 
so that they could be contacted for round 2 of the survey. Next, 
participants were asked to provide their input on the phases, steps 
and criteria (including inclusion, wording, grouping, order and any 
other comments). Specifically, they indicated whether each criterion 
should be omitted, possibly kept, or whether they considered the 
criterion to be essential or desirable to the process using a 4- point 
Likert scale (omit, possible, desirable and essential). Participants 
were also given the opportunity to provide rewording suggestions, 
suggest additional phases, steps or criteria or provide additional 
comments or questions. Participants were not required to provide 
qualitative feedback but had to select a response on the Likert scale 
for each criterion to progress through the survey. Participants could 
exit the survey at any time. The survey was open from 16 July to 
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1 September 2018. During that time period, two automated email 
reminders were sent to participants to complete the survey.
2.5.2 | Round 2 survey
Round 1 participants were invited to complete the round 2 survey 
via email. The round 2 survey included a summary of the round 1 
results: the percentage of participants who thought each criterion 
should be retained or excluded and the changes made based on the 
qualitative feedback. Participants were invited to indicate whether 
each criterion should be omitted, possibly kept, or whether they 
considered the criterion to be essential or desirable to the process 
using the same Likert scale as round 1. They could also provide ad-
ditional rewording suggestions, comments or questions for criteria 
that did not reach consensus in round 1 and new criteria proposed by 
participants during the first round. The survey was available from 24 
April to 31 May 2019. During that time frame, two automated email 
reminders were sent to participants to complete the survey.
2.6 | Data analysis
Following round 1, the ratings were summarized using percentages. 
If >80% of participants rated a criterion in the lower two catego-
ries (omit, possible) or in the higher two categories (desirable and 
essential), we considered consensus as having been reached and 
the criterion was removed or retained accordingly. Following the 
round 1 survey, a consensus meeting involving the steering group 
was held. The steering group reviewed and discussed the ratings and 
qualitative feedback, including rewording suggestions, suggestions 
to add new phases, steps or criteria, and more general comments or 
questions. The wording or order of the phases, steps or criteria were 
revised if two or more respondents suggested it or if the steering 
group members agreed that the phase, step or criterion would ben-
efit from rewording, reordering or merging. The same process was 
conducted following the round 2 survey.
Only fully completed surveys were included in the analysis. 
Based on the round 2 results and feedback, the steering committee 
deemed it unnecessary to conduct a third Delphi round. This method 
to determine the number of survey rounds was implemented suc-
cessfully in the past to develop a measure of organizational readi-
ness for patient engagement.28
3  | RESULTS
3.1 | Participants
In the first Delphi round, 50% (n = 131/260) of participants who 
started the survey completed it. The majority, 58% (n = 76), of re-
spondents were female. Overall, 26 countries were represented (see 
Table 1 for details). A total of 49% (64/131) of participants selected 
multiple roles (see Appendix S3 to view the roles of participants in 
the first Delphi round).
All 131 participants who completed the round 1 survey were 
invited to complete the second round Delphi survey. Of the par-
ticipants who started the round 2 survey, 95% (n = 114/120) com-
pleted it. Similar to round 1, the majority, 59% (n = 67), were female. 
Overall, 18 countries were represented in this round (see Table 1 
for details). A total of 50% (57/114) of participants selected multiple 
roles (see Appendix S3 to view the roles of participants in the second 
Delphi round).
3.2 | Survey results
The percentage of participants who rated each criterion desirable or 
essential in round 1 and round 2 is shown in Appendix S3. In round 
1, participants provided 763 general comments and the following 
specific suggestions: reword (n = 38), reorder (n = 27), add criteria 
TA B L E  1   Participant characteristics




Male, n (%) 54 (41) 47 (41)
Female, n (%) 76 (58) 67 (59)
Other, n (%) 1 (0) 0 (0)
Country
United States, n (%) 52 (40) 50 (44)
United Kingdom, n (%) 16 (12) 17 (15)
Australia, n (%) 6 (5) 7 (6)
Canada, n (%) 9 (7) 6 (5)
Other*, n (%) 48 (37) 34 (30)
Ethnicity
White, n (%) 113 (87) 95 (83)
Hispanic, Latino/a or 
Spanish origin, n (%)
4 (3) 2 (2)
Black or African American, 
n (%)
1 (0) 2 (2)
Asian, n (%) 7 (5) 9 (8)
Other, n (%) 6 (5) 6 (5)
Note: *Round 1: United States (n = 52), United Kingdom (n = 16), 
Canada (n = 9), the Netherlands (n = 8), Germany (n = 7), Australia 
(n = 6), Austria (n = 4), Switzerland (n = 3), Norway (n = 3), Ukraine 
(n = 3), Brazil (n = 2), Denmark (n = 2), France (n = 2), Finland (n = 2), 
Belgium (n = 1), Croatia (n = 1), Chile (n = 1), Italy (n = 1), Japan (n = 1), 
Nigeria (n = 1), Peru (n = 1), Philippines (n = 1), Portugal (n = 1), Romania 
(n = 1), Spain (n = 1) and Thailand (n = 1). 
Round 2: United States (n = 50), United Kingdom (n = 17), Australia 
(n = 7), Canada (n = 6), the Netherlands (n = 8), Norway (n = 5), 
Germany (n = 3), Denmark (n = 3), France (n = 2), Romania (n = 2), 
Switzerland (n = 2), Austria (n = 1), Belgium (n = 1), China (n = 1), 
Croatia (n = 1), Japan (n = 1), Malaysia (n = 1), Peru (n = 1), Philippines 
(n = 1) and Thailand (n = 1).
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(n = 23), merge criteria (n = 20), delete criteria (n = 4) and split cri-
teria (n = 1). In round 2, participants provided 91 general comments 
and the following specific suggestions: merge criteria (n = 7), reword 
criteria (n = 3) and delete criteria (n = 3). Of the 48 criteria in round 
1, 16 were removed, and 7 criteria were merged into 2 criteria. Thus, 
the round 2 survey had 27 criteria. The changes made after round 1 
are described in Appendix S4, and the results of the survey are pre-
sented per phase, with each round described separately.
3.3 | Phase 1: Define process and scope
3.3.1 | Round 1 (5 steps)
Between 70% and 95% of participants rated the 21 criteria in Phase 
1 as desirable or essential. Qualitative feedback suggested reword-
ing each of the three criteria in step 1 to specify the population 
and subpopulations, the reasonably relevant options for the deci-
sion (including no intervention if applicable), the outcomes and the 
patient concerns. Participants felt that the four criteria on the evi-
dence summarization process in step 2 were redundant. We there-
fore merged them into one criterion for the round 2 survey. Similarly, 
participants felt that the four criteria in step 4, each listing a differ-
ent stakeholder group that should be part of a team that develops 
a PDA, should be merged into one criterion. Participant feedback 
in step 3 suggested spelling out the COI abbreviation, and adding a 
fifth criterion to report all current and potential conflicts of interest. 
The general comments also led to the reordering of step 3 and step 
4 for the round 2 survey. Also, the following three criteria in step 5 
were rated as essential or desirable by 80% or less of participants: (i) 
there is a systematic process to reduce bias in the definition of the 
population for the PDA; (ii) there is a systematic process to reduce 
bias in the definition of the options for the PDA; and (iii) there is a 
systematic process to reduce bias in the definition of the outcomes 
or patient concerns for the PDA. The ratings and qualitative feed-
back led to the removal of step 5 in the round 2 survey. Lastly, par-
ticipants suggested adding examples to clarify many of the criteria in 
each step of Phase 1. We added the following example for the first 
criteria in step 1: ‘For example, for early stage breast cancer surgery, 
you will select and summarize evidence about women aged 18 or older 
with early stage breast cancer stages 1 to 3A If the subpopulation of 
interest is women over 70 years old or African American women, you will 
synthesize evidence related to early stage breast cancer surgery for this 
group, if it is available’.
3.3.2 | Round 2 (4 steps)
Between 86% and 100% of participants rated the ten criteria in 
Phase 1 as desirable or essential.
Based on qualitative feedback, the criteria in step 3 (‘Assemble 
the team’) should include a larger stakeholder group to ensure mul-
tiple voices prevent the development of a biased PDA. General 
comments in step 4 (‘Manage conflicts of interest’) explained how 
PDAs should report a clear, succinct conflict of interest statement. 
For research teams that develop a suite of PDAs, it may be more 
practical to have a blanket conflict of interest statement or have the 
statement be available upon request from the authors. Participants 
also suggested merging the five criteria in step 4, so that it reads: 
‘collect, manage, monitor, and report conflicts of interest’ to avoid 
repetition.
3.4 | Phase 2: Finding and appraising evidence
3.4.1 | Round 1 (3 steps)
Between 79% and 94% of participants rated the 12 criteria in Phase 
2 as desirable or essential. The majority of the participant qualita-
tive feedback focused on rewording the criteria in steps 1 and 2 to 
be more concise. The five criteria in step 3 (‘Appraise the evidence’) 
were considered redundant and, based on feedback, were merged 
into two criteria for the round 2 survey: (a) critically appraise for risk 
of bias at study level, and (b) critically appraise quality or certainty 
of the body of evidence. Examples, where suggested by participants, 
were inserted to help clarify criteria. For instance, participants 
wanted an example of how to account for risk of bias in study design, 
so we added the following to the second criteria in step 7: For exam-
ple, you may use The Cochrane Risk of Bias Tool.
3.4.2 | Round 2 (3 steps)
Between 86% and 100% of participants rated the nine criteria in 
Phase 2 as desirable or essential. To avoid redundancy, participants 
suggested merging two of the criteria in step 2 so that it reads: 
‘Systematically select evidence about benefits and harms of each 
option’. Overall, the qualitative feedback indicated that partici-
pants wanted more detail on the hierarchy, grading and sources of 
evidence. Evidence embedded in PDAs should be derived from sys-
tematic reviews. GRADE should be followed to rate the quality of ev-
idence as determined by systematic reviews. The certainty or quality 
of the evidence should also be critically appraised. Grey literature 
and social media sources should be avoided unless patient- relevant 
harms and benefits and concerns are not sufficiently covered in bio-
medical databases of published literature.
3.5 | Phase 3: Presenting evidence and evidence 
summarization process
3.5.1 | Round 1 (4 steps)
Between 74% and 98% of participants rated the 14 criteria in 
Phase 3 as desirable or essential. The majority of the qualitative 
comments focused on the redundancy of the criteria in this phase. 
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We therefore reworded the first four criteria in step 1 to be more 
concise, and we removed the last two criteria for the round 2 sur-
vey to avoid redundancy. Furthermore, the three criteria in step 2 
(‘Manage COI’) were considered by participants to be too similar to 
the criteria in step 3 of Phase 1, so we removed them for the round 
2 survey. Based on participant feedback, two of the four criteria 
in step 3 (‘Report’) were removed to avoid redundancy, and the 
remaining criteria were reworded for the round 2 survey: (a) report 
the methods used to represent the evidence, and (b) report the 
evidence summarization process publicly and in a way that is easy 
to understand. Examples, where suggested by participants, were 
inserted to help clarify criteria. For instance, participants wanted 
some guidance on how to present evidence in a way that is easy 
to understand, so we provided an example in the third criteria of 
step 8: For example, the IPDAS chapter on communicating evidence 
may be used.
3.5.2 | Round 2 (3 steps)
Between 84% and 96% of participants rated the seven criteria in 
Phase 3 as desirable or essential. Based on qualitative feedback, 
participants wanted more information in step 1 on how to present 
risk information in a balanced fashion considering the difficulty of 
this task. PDAs should use absolute risks instead of relative risks. 
Also, participants sought more detail on the external group in step 3. 
The criteria should be explicit on the make- up of the external group, 
which should include patients to assess how to best present the 
evidence.
3.6 | Phase 4: Post- publication update
3.6.1 | Round 1 (1 step)
Step 1 (‘Update’) had one criterion that was rated desirable or essen-
tial by 90% of participants: the PDA content is updated when new 
evidence becomes available. Based on qualitative feedback, the step 
1 title was reworded to ‘Update the evidence’ and the criterion was 
reworded for the round 2 survey so that it reads: ‘specify process for 
updates when new evidence becomes available’. Participants sug-
gested that we add an example to the final step and criteria to clarify 
what is meant by ‘updating the evidence’. We added the following: 
For example, the evidence will be updated every year or whenever new 
relevant evidence is published.
3.6.2 | Round 2 (1 step)
The criterion was rated as desirable or essential by 90% of partici-
pants. Qualitative feedback indicated that participants were con-
cerned about the practicality of updating the PDA every time new 
evidence becomes available. Updating the evidence is a time- and 
resource- intensive process that requires funding. Guidelines should 
also be developed to identify when and who updates the evidence. 
Relatedly, to increase feasibility, participants felt that a benchmark 
should be established to update the evidence of PDAs (eg updates 
are required every three years). Participants also suggested includ-
ing publication dates on PDAs.
3.7 | Final process
Overall, the process for selecting and summarizing evidence for 
PDAs went from five phases consisting of 13 steps and 48 crite-
ria (Round 1) to four phases consisting of 11 steps and 31 criteria 
(Round 2). Oversight at the beginning of the Delphi process led 
to the omission of a criterion about the systematic search for the 
evidence about the effects on the outcomes for each option in the 
PDA. This oversight was only realized after the completion of the 
second round of the Delphi survey. At the conclusion of the Delphi 
process, this criterion was added based on unanimous consensus by 
the steering group members. An editorial process was undertaken 
by the steering group to summarize the evidence summarization 
process for an external audience. The brief, easy- to- read summary 




Based on two rounds of a modified Delphi survey, we have devel-
oped a process for selecting and summarizing evidence for PDAs 
that now consists of four phases, 11 steps and 31 criteria. Based on 
the stakeholders’ feedback, the number of steps was reduced from 
13 to 11, and the criteria from 48 to 31 by merging or deleting redun-
dant criteria. The qualitative feedback also informed the rewording 
of criteria and the addition of examples to improve the clarity of the 
process for PDA developers. The final 31 criteria were rated as desir-
able or essential by 84% to 100% of participants.
4.2 | Strengths and limitations
Our use of the Delphi method to obtain feedback from a multi-
disciplinary stakeholder group to develop the PDA evidence sum-
marization process is a strength, and the use of this method is 
supported when evidence is weak or uncertain. There is a dearth 
of empirical evidence for an evidence summarization process spe-
cific to PDA development. This group included patients in each 
round of the Delphi survey, ensuring that the patient perspective 
is included in the evidence summarization process. We believe 
that a major strength of our evidence summarization process is 
that it encourages the involvement of patients throughout the 
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process and can be used to develop tools for all patient popula-
tions, including those who are underrepresented. In terms of limi-
tations, the high attrition rate in the Round 1 survey decreased 
the size of our sample and may have led to a non- response bias. 
Also, we do not know the total number of participants invited to 
the Round 1 survey because we are unable to determine the total 
number of potential participants from each listserv. The consist-
ent ‘desirable or essential’ ratings suggest a ceiling effect, which 
could be reduced in future Delphi studies by substituting a 4- point 
scale with a 5- point scale that includes 3 positive and 2 negative 
choices.28,29 The evidence summarization process has also yet to 
be piloted. Lastly, the omission of a criterion from the Delphi pro-
cess prevented participants from providing feedback on whether 
it is desirable or essential to the evidence summarization process.
4.3 | Results in context
Our study addresses a significant gap in PDA development guidance 
by presenting the first process for selecting, summarizing and re-
porting evidence in PDAs. Prior to the development of this process, 
the following five items in the IPDAS checklist were the only source 
of guidance for the selection and summarization of evidence to be 
included within PDAs: the PDA provides citations to the studies 
selected, describes how research evidence was selected or synthe-
sized, provides a production or publication date, provides informa-
tion about the proposed update policy, and describes the quality 
of the research evidence used.9 However, as highlighted by Zadro 
et al, further guidance is needed on how to present evidence, and 
how to communicate the uncertainty of evidence.30,31 For instance, 
Steps Criteria
Define the decision Specify the relevant population and/or subpopulations.
Specify the relevant reasonable options for the decision, and if 
applicable, include no treatment or testing.
Specify relevant outcomes and patient concerns for this decision.
Report processes 
and policies
Make public the proposed evidence summarization process in easy- to- 
understand language.
Make public the conflict of interest policy.
Assemble editorial 
team
Assemble a multistakeholder team (eg patients, relevant clinicians, 
evidence/methodological and other experts).
Manage editorial 
team conflicts of 
interest
Collect and update conflicts of interest.
Manage conflicts of interest.
Report conflicts of interest.
Systematic search Search for evidence about the appropriateness of options to include.
Search for evidence about patient concerns relevant to the options. 
(Patient- centred outcomes and concerns may require additional 
searches and/or research).
Search for evidence about the effects of the options on the relevant 
outcomes (including likelihood of harms and benefits).
If personal risk calculation occurs in the aid, systematically search for 
evidence about predictive factors.
Systematic selection 
and appraisal
Select and appraise the evidence about the relevant outcomes 
(including the likelihood of harms and benefits).
Select and appraise the evidence about patient concerns relevant to 
the options.
Identify evidence gaps.
If personal risk calculation occurs in the aid, select and appraise 
evidence about predictive factors.




Present the evidence for benefit (or evidence gaps) in a balanced way.
Present the evidence for harms (or evidence gaps) in a balanced way.
Present evidence in easy- to- understand formats, following the best 
practice principles.
Present the certainty of the evidence in a way that is easy to 
understand.
Present the evidence in plain language.*
External review Describe the method of seeking external review by relevant 
stakeholders.
Update process Describe the update plan (search, selection, appraisal of new 
evidence).
*Methods to translate from one language to another are not covered and require further work. 
TA B L E  2   Criteria for patient decision 
aid evidence selection and summarization 
(see Appendix S4 for details)
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presenting evidence in a ‘balanced’ way can be troublesome in sit-
uations where there is evidence of much more benefit than harm 
or vice versa. Often, options have very little evidence of harms or 
benefits, so presenting evidence in a ‘balanced’ fashion is not fea-
sible. This is an issue that needs further clarification. The process 
we have developed with the input of a multidisciplinary stakeholder 
group provides guidance about criteria to consider when including 
evidence in a PDA.
4.4 | Implications
Without a transparent and articulated process for summarizing and 
presenting evidence, PDAs may not contain an accurate and up- to- 
date summary of the appropriate evidence or present information 
about evidence quality and certainty. This has implications on the 
decision- making process, as the evidence that is included in PDAs 
can influence the decisions that patients make. Having a process in 
place may help address frequent concerns from clinicians that im-
portant information is missing from PDAs and that numerical data 
are poorly presented.32 Our evidence summarization process ad-
dresses these concerns by providing guidance about what should be 
involved in the process for selecting, summarizing and presenting 
evidence in PDAs. Future research should involve the piloting of this 
process with PDA developers and the exploration of how this pro-
cess can be linked with IPDAS to improve the content and develop-
ment of PDAs.
5  | CONCLUSION
Ratings and qualitative feedback from over 100 multidisciplinary 
stakeholders across 28 countries in two Delphi survey rounds led to 
the development of a set of criteria for selecting, summarizing, re-
porting and updating evidence in PDAs. PDAs are promoted as tools 
that provide evidence- based, trustworthy information. Widespread 
adherence to the proposed criteria will help ensure that these tools 
fulfil that promise.
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